Is axitinib effective?

Axitinib has shown promising efficacy in the treatment of advanced renal cell carcinoma. As a targeted therapy drug, axitinib inhibits vascular endothelial growth factor receptor (VEGFR), blocks neovascularization of tumors and slows down the progression of the disease. Clinical trials and practical application studies have shown that axitinib can significantly extend patients' survival, slow down the progression of the disease, and improve quality of life. Especially in patients who are resistant to other treatments, axitinib as a first- or second-line treatment option brings more treatment opportunities to patients. However, the specific efficacy also depends on the patient's individual situation, and the treatment plan should be formulated by a professional medical team based on the patient's pathological characteristics and overall health status.